Condition: Carcinoma, Hepatocellular · Sponsor: Shanghai Henlius Biotech
The study is being conducted to to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) Failed or Intolerance to Standard Therapy
This description comes directly from the study's public registry record.
Hua Xiang, Dr. · 0731-89762040 · 2805566465@qq.com
Shanzhi Gu, Dr · 0731-89762040 · 105575191@qq.com
Always discuss trial participation with your own doctor first.
| Hunan Cancer Hospital | Hunan, Hunan, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06742892